Banka BioLoo Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Banka BioLoo Limited submitted its unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended 30 June 2025). On a standalone basis, revenue from operations rose marginally to Rs. 1,255.82 lakhs (vs Rs. 1,238.75 lakhs in Q1 FY25), but profit after tax fell sharply to Rs. 13.54 lakhs (vs Rs. 42.29 lakhs) due to higher operating expenses and depreciation. Consolidated revenue declined about 13.5% YoY to Rs. 1,114.12 lakhs, with consolidated PAT nearly flat at Rs. 0.21 lakhs. The auditor (B.D. Saboo & Associates) issued an unmodified limited review report with no qualifications. The Board also approved re-appointment of Mr. Sanjay Banka as Executive Chairman and Mr. Vishal Murarka as CEO for three years, appointed Mrs. Geeta Goti as a Woman Independent Director, and fixed the 13th AGM for 10 September 2025.
Marginal topline growth was more than offset by rising costs, leading to a sharp drop in standalone profitability and a near-zero consolidated profit, which is negative for short-term earnings sentiment. The Board changes are routine re-appointments and a new independent director, unlikely to materially move the stock. Shareholders should watch for sustained cost control and revenue recovery in coming quarters.